What do healthcare providers think of the iManageCancer project?

Editor's choice for January 2016

Utilising disease heterogeneity and emerging biomarkers to individualise prostate treatment

The ManVan: a mobile cancer support service for men with prostate, testicular and penile cancer in Wales

Entinostat and high-dose Interleukin 2 in renal cell carcinoma patients

Gemcitabine plus cisplatin plus ipilimumab for metastatic urothelial cancer

Avelumab for metastatic urothelial carcinoma: JAVELIN trial

Subgroup analyses of METEOR; randomized phase III trial of cabozantinib vs everolimus for RCC

Integrated genomic correlates of response to PD-1 inhibitor nivolumab in mRCC

Discontinuing VEGF-targeted therapy for progression or toxicity affects outcomes of second-line therapies in mRCC

Impact of metformin on outcomes for metastatic renal cell carcinoma

Comparing adjuvant radiotherapy plus chemo vs. adjuvant chemo following cystectomy for bladder cancer